Transcript Document
Advanced Bioinformatics
Lecture 6: Pharmacology and drug development
ZHU FENG [email protected]
http://idrb.cqu.edu.cn/ Innovative Drug Research Centre in CQU
创新药物研究与生物信息学实验室
Table of Content
1. Modern drug development 2. Drug & corresponding target 3. Mechanism of drug binding 4. Mechanism of drug action 5. Adrenoceptor cardiac function 2
2013 ranking of the global top 10 pharmaceutical companies based on revenue 40.0
+ 15.0
+ 3.8
+ 1.8
= 60.6
3 Revenue in billion U.S. dollars
Top 10 drugs ranked by sales for Q1 2013
5 6 7 8 9 10
Rank
1 2 3 4
Brand Name(s) Generic Name
Abilify Nexium Cymbalta Crestor Seretide Humira Enbrel Remicade Copaxone Neulasta Aripiprazole Esomeprazole Duloxetine Rosuvastatin Fluticasone + Salmeterol Adalimumab Etanercept Infliximab Glatiramer Filgrastim
Sales (billion USD) 1.5
Company
Otsuka, BMS
1.4
1.3
1.3
AstraZeneca Eli Lilly AstraZeneca, Shionogi
Therapeutic Class
Depression Dyspepsia Depression Cholesterol
1.3
GSK Asthma
1.2
1.1
1.0
0.9
0.9
Abbott Amgen J&J, Merck Teva, Sanofi Aventis Amgen Rheumatoid arthritis Rheumatoid arthritis Rheumatoid arthritis Multiple sclerosis Neutropenia
Approval Year
2002 2000 2004 2002 2000 2002 1998 1998 1996 2002
4
Traditional drug design
Random screening against disease assays
Natural products, synthetic chemicals, etc Long design cycle: 7-12 years High cost: 350 million USD per marketed drug Too slow and costly to meet demand Drug Discovery Today 2, 72-78 (1997) 5
Modern drug development
Rational drug design and testing
Speed-up screening process
Efficient screening (focused, target directed)
Computer aided drug design (target directed)
Integration of testing into design process
Fail drugs fast (remove hopeless ones AEAP) 6
Strategies for improving design cycle
Smart screening:
−
High-throughput robotic screening Diversity of chemical compounds:
−
Combinatorial chemistry High expectation Nature 384 Suppl., 2-7 (1996) 7
Any other alternative approach?
Current situation:
−
Molecular mechanism of disease processes, structural biology.
−
Rising cost of experimental equipment and resources.
−
Computer revolution (low cost, high power).
−
Software development.
Natural conclusion: computer approach?
8
Strategies for improving design cycle
Computer-aided drug design:
−
Receptor 3D structure unknown Receptor-based drug design (QSAR)
−
Receptor 3D structure known Ligand-based drug design (Docking) Science 257, 1078-1082 (1992) 9
The stages of development of a ‘typical’ new drug
Overall cost per marketed compound is ₤250-500 million and the typical time scale is 8-12 years. Only about 1 in 12 entering development succeeds in reaching the market 10
Key go/no-go decisions for developing a drug Key decision gates in drug development
Drug candidate selection
Key questions and pivotal studies Bio-stability Metabolism Bioavailability Cytotoxicity Dosage Synthesis Formulation 12
Drug safety indicators
Key questions and pivotal studies Formulation Dosage Safety margin Metabolism Metabolism Effects on heart Effects on lung 13
Pharmacology today with its various subdivisions 14
Drug & corresponding target
15
Drug target: receptor
Receptors are the sites at which molecules such as hormones and neurotransmitters are recognised. A drug that binds to a receptor can be:
Agonist: trigger the same events as the native ligand.
Antagonist: stop bind of the native agent without eliciting a response There are four ‘superfamilies’ of receptors 16
Types of receptor-effector linkage
17
Drug target: enzyme
Proteins catalyzing reactions required for cellular function. Specific for particular substrate or family of substrates. Inhibitor restricts action of enzyme on its substrate. Inhibitors may be irreversible or reversible.
Reversible inhibitors: Competitive & Non-competitive. Enzyme inhibitors might be seen to allow very ‘fine control’ of cellular processes.
18
Drug target: nucleic acids
Designing compounds that can distinguish target nucleic acid sequences is not yet achievable.
There are compounds with planar aromatic regions that bind in-between the base pairs of DNA or to the DNA grooves. These generally inhibit the processes of DNA manipulation required for protein synthesis and cell division.
Suitable for aiming at promoting cell death. 19
Bio-chemical class distribution for successful & clinical trial targets Fig 1 BioChemical Class Distribution for Successful Targets (348)
Channels and Transporters 12% Receptor 24% Factors and Regulators 6% Nuclear Receptor 4% Binding protein/Antigen 4% Enzyme 46% Structure Proteins 3% Nucleic Acid 1%
Fig 2 BioChemical Class Distribution for Clinical Trial Targets (295)
Receptor 24% Channels and Transporters 8% Factors and Regulators 11% Nuclear Receptor 1% Binding protein/Antigen 5% Structure Proteins 3% Enzyme 40% Nucleic Acid 8%
20
Mechanisms and specificity of drug binding
The majority of binding and recognition occurs through non covalent interactions.
These govern:
The folding of proteins and DNA.
The association of membranes.
Molecular recognition (e.g. interaction between an enzyme and its substrate or the binding of an antibody).
They are generally weak and operate only over short distances. As a result large numbers of these interactions are necessary for stability, requiring a high degree of complementarity between binding groups and molecules. 21
Drug binding site in a cavity of protein
HIV-1 protease 22
Mechanism of drug binding and actions
Lock and key:
blocking => stopping of protein function
HIV-1 protease complex with SB203238 23
Covalent bonds
The ‘sharing’ of a pair of electrons between two atoms.
A very stable interaction Requires hundreds of kilojoules (kJ) to disrupt Compounds that inhibit enzymes through formation of covalent interactions are called ‘suicide inhibitors’.
Not all covalent bond formation is irreversible
Hydrolysis Action of repairing proteins 24
Non-covalent interactions
The forces involved are:
Hydrogen bonds van der Waals forces Ionic / electrostatic interactions Hydrophobic interactions Generally, such interactions are weak:
Vary from 4-30 kJ/mol 25
Selectivity, toxicity and therapeutic index
Drugs may bind to both their desired target and to other molecules in an organism.
If interactions with other targets are negligible then a drug is said to be specific.
In most cases drugs will show a non-exclusive preference for their target - selective.
The interaction with both their intended target and other molecules can lead to undesirable effects (side effects).
26
Selectivity, toxicity and therapeutic index
Establish the concentrations at which the drug exerts its beneficial effect and where the level of side effects becomes unacceptable.
Commonly used values are ED50 and LD50.
For obvious reasons LD50 tests are not carried out on human volunteers!
One measure of the margin of safety is the therapeutic index. Therapeutic index = LD50 / ED50
Drugs with low therapeutic indices are only used in ‘life or death’ type situations.
27
Agonists & antagonists
Activity of a drug is the result of two independent factors:
Affinity is the ability of a drug to bind to its receptor Efficacy is the ability of the bound drug to elicit a response There are 2 classes of agonist
Full agonists – which elicit the maximum possible response at some concentration
Partial agonists – which never elicit the maximum possible response from the receptor There are 2 classes of antagonist
Competitive – which compete for the agonist binding site, and require higher agonist concentration to elicit a given response.
Non-competitive – these bind at a site other than the agonist binding site, or even to a completely different molecular target. The result is the lowering of the maximum possible response in addition to the usual antagonist effect of ‘displacing’ agonist activity to higher concentration. 28
Case study
Adrenoceptor and control of cardiac function Adrenoceptor is receptor for two important hormones : adrenaline (
肾上腺素
) and noradrenaline (
去甲肾上腺素
).
Widely distributed, being responsible for control of the stimulation and relaxation of muscle , including the heart.
Mediate the control of cardiac function by the sympathetic nervous system; the parasympathetic nervous system control is mediated by muscarinic acetylcholine receptors.
Remember that cytoplasmic [Ca2+] regulates the development of tension in muscles , such as the heart.
29
Case study
Adrenoceptor and control of cardiac function The activation of and adrenoceptors usually elicits opposing responses:
receptor activation leads to constriction veins and arterioles.
of
receptor activation leads to dilation and arterioles.
of veins 30
Function of adrenoceptors in heart & vascular system Epinephrine administered rapidly intravenously has a number of simultaneous effects that contribute to a rapid rise in blood pressure on its administration.
A rise in the strength of ventricular contraction (a positive inotropic action)
The heart rate is increased (a positive chronotropic action)
Blood vessels become constricted .
Noting the opposing roles of
and
receptors, it may be no surprise to discover that administration regimes other than rapidly intravenous injection can have quite different effects .
31
1 and
2 -adrenoceptor ’s activation leads to constriction of vascular smooth muscle
1 and
2 -adrenoceptor ’s activation leads to Ca 2+ influx, relaxation of vascular smooth muscle, so enhances contraction and increase heart rate.
3 and
4 -adrenoceptor ’s presence in heart is not fully established, and their role is even more uncertain.
32
1
-adrenoceptor agonists
Treat hypotension through vasoconstriction, leading to increased blood pressure. Also valuable adjuncts to local anaesthetics , as vasoconstriction can slow the systemic dispersal of the anaesthetic.
Drugs in this class include: Phenylephrine Methoxamine 33
2
-adrenoceptor agonists
Treat hypertension , through action at the CNS, reducing signal to the heart and so lowering cardiac activity and constriction of the peripheral vasculature.
Drugs in this class include: Methyldopa Clonidine 34
-adrenoceptor agonists
Treat hypotension , cardiac arrhythmias & cardiac failure . Stimulate the rate and force of cardiac contraction, and lead to a drop in peripheral vascular resistance.
Drugs in this class include: Xamoterol Dobutamine 35
1
-Adrenoceptor antgonists
Inhibiting the action of endogenous vasoconstrictors, resulting in vasodilation of both arteries and veins, and thus reduction of blood pressure . Treating hypertension and cardiac failure .
Drugs in this class include: Prazosin Indoramin 36
2
-Adrenoceptor antgonists
Just as
2 -adrenoceptor agonists unexpectedly reduce vasoconstriction and lower cardiac activity, their antagonists cause a rise in blood pressure .
Yohimbine is an
2 - adrenoceptor antagonist.
Yohimbine 37
-Adrenoceptor antgonists
Treating hypertension , angina and ischemic heart disease , also cause an increase in peripheral resistance to blood flow, although this effect is reversed on prolonged administration.
Drugs in this class include: Propanolol Metoprolol 38
Projects Q&A!
1. Biological pathway simulation 2. Computer-aided anti-cancer drug design 3. Disease-causing mutation on drug target
Any questions? Thank you!
39